Literature DB >> 6681623

Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay.

D C Rijken, I Juhan-Vague, F de Cock, D Collen.   

Abstract

A two-site immunoradiometric assay for human extrinsic (tissue-type) plasminogen activator was developed by using rabbit antibodies raised against plasminogen activator purified from human melanoma cell culture fluid. Samples of 100 microliters containing 1 to 100 ng/ml plasminogen activator were incubated in the wells of polyvinyl chloride microtiter plates coated with antibody. The amount of bound extrinsic plasminogen activator was quantitated by the subsequent binding of 125I-labeled affinospecific antibody. The mean level of plasma samples taken at rest was 6.6 +/- 2.9 ng/ml (n = 54). This level increased approximately threefold by exhaustive physical exercise, venous occlusion, or infusion of DDAVP. Extrinsic plasminogen activator in plasma is composed of a fibrin-adsorbable and active component (1.9 +/- 1.1 ng/ml, n = 54, in resting conditions) and an inactive component that does not bind to a fibrin clot (probably extrinsic plasminogen activator-proteinase inhibitor complexes). The fibrin-adsorbable fraction increased approximately fivefold to eightfold after physical exercise, venous occlusion, or DDAVP injections. Potential applications of the immunoradiometric assay are illustrated by the measurement of extrinsic plasminogen activator in different tissue extracts, body fluids, and cell culture fluids and in oocyte translation products after injection with mRNA for plasminogen activator.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6681623

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  10 in total

1.  A controlled study of stanozolol in primary Raynaud's phenomenon and systemic sclerosis.

Authors:  M I Jayson; C D Holland; A Keegan; K Illingworth; L Taylor
Journal:  Ann Rheum Dis       Date:  1991-01       Impact factor: 19.103

2.  Localization of the binding site of tissue-type plasminogen activator to fibrin.

Authors:  A Ichinose; K Takio; K Fujikawa
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

3.  Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components.

Authors:  M Colucci; J A Paramo; J M Stassen; D Collen
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

4.  Binding of tissue plasminogen activator to cultured human endothelial cells.

Authors:  K A Hajjar; N M Hamel; P C Harpel; R L Nachman
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

Review 5.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

6.  Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity.

Authors:  R I Levin; P C Harpel; D Weil; T S Chang; D B Rifkin
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

7.  Plasminogen activation in plasma of patients with systemic lupus erythematosus.

Authors:  N Negoro; Y Kanayama; T Takeda; M Fujisawa; M Okamura; T Inoue
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

8.  Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells.

Authors:  E G Levin; U Marzec; J Anderson; L A Harker
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

9.  Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.

Authors:  M Colucci; J A Paramo; D Collen
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

10.  Postoperative changes in plasma tissue-type plasminogen activator and type 1 plasminogen activator inhibitor.

Authors:  K Aoki; N Nishino; S Baba; T Urano; A Takada
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.